To all our CKB CORE users, don’t miss the latest new features now available! Register for a free CORE account here and then login for access. Feel free to contact us at ckbsupport@genomenon.com if you have any questions!

Molecular Profile Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Profile Name CD274 over exp
Gene Variant Detail

CD274 over exp (no effect)

Relevant Treatment Approaches PD-L1/PD-1 antibody

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
CD274 over exp STK11 mut lung adenocarcinoma not predictive unspecified immune checkpoint inhibitor Clinical Study - Cohort Actionable In a clinical study, lung adenocarcinoma patients with high expression of CD274 (PD-L1; >/= 50%) and a co-occurring STK11 mutation demonstrated a similar objective response rate (P=0.2), progression-free survival (P=0.29), and overall survival (0.44) compared to patients with negative expression of CD274 (PD-L1) and a co-occurring EGFR mutation when treated with an unspecified immune checkpoint inhibitor (PMID: 32178965). 32178965
CD274 over exp TP53 mut lung adenocarcinoma predicted - sensitive unspecified immune checkpoint inhibitor Clinical Study - Cohort Actionable In a clinical study, lung adenocarcinoma patients with high expression of CD274 (PD-L1; >/= 50%) and a co-occurring TP53 mutation demonstrated a greater objective response rate, 39.8% (35/88) vs 18.3% (13/71); P=0.005, progression-free survival (HR=0.62, P=0.006), and overall survival (HR=0.65, P=0.04) compared to patients with negative expression of CD274 (PD-L1) and a co-occurring KRAS mutation when treated with an unspecified immune checkpoint inhibitor (PMID: 32178965). 32178965
ALK rearrange CD274 over exp lung adenocarcinoma predicted - sensitive Atezolizumab + Bevacizumab + Carboplatin + Pemetrexed Disodium Case Reports/Case Series Actionable In a clinical case study, a patient with ALK-rearranged lung adenocarcinoma with high CD274 (PD-L1) expression (TPS>=50%) who progressed on 3 prior ALK inhibitors experienced a rapid and ongoing clinical improvement with the combination therapy of Tecentriq (atezolizumab), Avastin (bevacizumab), Paraplatin (carboplatin), and Alimta (Pemetrexed Disodium), achieving decreased lung lesion size, complete metabolic response of liver lesions, and partial response of bone lesions (PMID: 34336591). 34336591
CD274 over exp POLE R34L small intestine adenocarcinoma predicted - sensitive Pembrolizumab Case Reports/Case Series Actionable In a clinical case study, Keytruda (pembrolizumab) treatment resulted in a reduction of primary tumor and metastatic lesions and an ongoing progression-free survival at 31 months in a patient with microsatellite stable (MSS) ileum adenocarcinoma that had high CD274 (PD-L1) expression (TPS = 75%) and harbored POLE R34L, but had low tumor mutational burden (PMID: 34875656). 34875656
CD274 over exp STK11 A205Rfs*82 lung squamous cell carcinoma predicted - resistant Pembrolizumab Case Reports/Case Series Actionable In a clinical case study, a lung squamous cell carcinoma patient with high CD274 (PD-L1) expression progressed after initial response to Keytruda (pembrolizumab) and through subsequent ctDNA testing was found to have acquired STK11 A205Rfs*82 (PMID: 33832284). 33832284
BRAF V600E CD274 over exp lung adenocarcinoma predicted - sensitive Dabrafenib + Trametinib Case Reports/Case Series Actionable In a clinical case study, second-line treatment with the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) resulted in a clinical response lasting at least 5 years in a patient with lung adenocarcinoma harboring BRAF V600E and high CD274 (PD-L1) expression (TPS=100%) who did not respond to first-line Keytruda (pembrolizumab) (PMID: 38429896). 38429896